Coagulation analyzers are mainly applied for laboratory tests of thrombosis and hemostasis, which can provide valuable indicators for the diagnosis and differential diagnosis of hemorrhagic and thrombotic diseases, detection, and efficacy of thrombolytic and anticoagulant therapy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, received FDA approval to streamline the stool collection process for ColoSense®, its RNA-based colorectal cancer (CRC) screening test. The newly approved collection kit no longer requires patients to separate their sample into multiple containers. This improves ease of use and reduces barriers to at-home screening,¹ while maintaining clinical performance.

Mirxes said Wednesday that is has partnered with Nagawa Pharmaceutical to accelerate development and implementation of its early cancer screening tests across Japan.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2025 and raised full-year guidance.

Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER). Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® pTau181 test to measure phosphorylated Tau (pTau) 181 protein which is an indicator of amyloid pathology, a hallmark of Alzheimer’s disease. The test, which has been developed in collaboration with Eli Lilly and Company, can be used by clinicians in conjunction with other clinical information to rule out Alzheimer’s disease as the cause of cognitive decline. This could avoid the need for further confirmatory investigation for patients testing negative.

Australian molecular diagnostics developer Genetic Signatures has signed a strategic partnership with lab automation solutions provider Tecan and in vitro diagnostic software developer Repado. Announced on Tuesday, the partnership aims to create a scalable suite of fully integrated syndromic infectious disease testing systems. Financial terms were not disclosed.

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025.

Shares of Oxford Nanopore Technologies jumped 16 percent on Monday after the company reported strong preliminary revenues for the first half of 2025.

Cardiovascular disease remains the leading cause of death worldwide. More than half a billion people around the world continue to be affected by cardiovascular diseases, which accounted for 20.5 million deaths in 2021 – close to a third of all deaths globally and an overall increase on the estimated 121 million CVD deaths.